Chemotherapy-Induced Febrile Neutropenia Pipeline Insights: Emerging Therapies and Companies

Strategic Insights -

The Chemotherapy-Induced Febrile Neutropenia (CIN) pipeline is a rapidly growing area of research, with over four key companies actively developing more than four therapeutic candidates for CIN treatment. DelveInsight's "Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025" report provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chemotherapy Induced Febrile Neutropenia Therapeutics Market. The report highlights the pipeline landscape, therapeutic assessment, and emerging drugs under development.

Key Takeaways:

  • DelveInsight's CIN pipeline report highlights an active landscape with over four companies developing more than four therapeutic candidates for CIN treatment.
  • Ryzneuta, approved in November 2023, is a long-acting G-CSF indicated to reduce the risk of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy.
  • Rolvedon, approved in September 2022, is another long-acting G-CSF designed to decrease the incidence of infection, as manifested by febrile neutropenia, in adults undergoing myelosuppressive chemotherapy.
  • Key players such as BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin SinoBiotech Ltd., Evive Biotech, and others are actively evaluating new therapies to improve the CIN treatment landscape.
  • Promising pipeline candidates in development include Plinabulin, EC-18, and others in various stages of clinical evaluation.

Statistics:

  • 4+ companies are actively developing more than 4 therapeutic candidates for CIN treatment.
  • The pipeline landscape includes 4+ products under different phases of clinical development.
  • 4+ libraries are developing therapies for CIN treatment.
  • Prevalence of CIFN in major cancers: breast (15%), colon (20%), lymphoma (25%), lung (30%), and ovarian (35%).
  • Incidence of FN in these cancers ranged from 7% to 30%.
  • Ryzneuta was approved in November 2023, and Rolvedon was approved in September 2022.

Sources:

  • DelveInsight's "Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025" report.
  • M2 COMMUNICATIONS RDATE:26082025.
  • www.abnewswire.com.